Dermatology News

Among patients with rheumatic diseases, the risk for cardiovascular comorbidity is highest during the period immediately before or after initial diagnosis, according to data published in Seminars in Arthritis and Rheumatism.

Izokibep achieved the primary endpoint of ACR50 response in a phase 2b/3 psoriatic arthritis trial, and demonstrated sustained, “deepening” benefit in hidradenitis suppurativa, according to top-line data from its manufacturer.

SAN DIEGO – The American Academy of Dermatology’s Advisory Board has voted to not adopt the resolution to dismantle and remove all current diversity, equity and inclusion programs.

SAN DIEGO The Skin of Color Society has released an official statement in opposition of the recently proposed resolution to eliminate all diversity, equity and inclusion programs at the American Academy of Dermatology.

SAN DIEGO — In a real-world setting, treatment with home-based phototherapy was noninferior to office phototherapy for people with plaque or guttate psoriasis, with both options safe and efficacious, according to a speaker here.

Screening patients with psoriasis, uveitis or inflammatory bowel disease for spondyloarthritis could improve early diagnosis, but no existing screening tools are generalizable to all who are at risk, according to a scoping review.

Pregnant patients with lupus or antiphospholipid syndrome have a higher risk for preterm birth, although immune-mediated inflammatory diseases in general are “only weakly associated” with adverse pregnancy outcomes, according to data.

The results of the second annual national primary care scorecard suggest the field is facing major problems — poor funding and a diminishing workforce, among them — but increased attention on the issues may offer hope, according to experts.

The FDA has approved Simlandi as the third interchangeable biosimilar to Humira following a rejection in April 2023 stemming from issues at the developer’s manufacturing facility.

SCOTTSDALE, Ariz. — Interleukin-17 targeting, a tyrosine kinase 2 inhibitor and the “nanobody revolution” represent a promising new frontier for psoriatic arthritis, according to a speaker here.